Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode

NCT00216671 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.

NCT NCT00216671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00216671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2005
Completion date
December 31, 2009
Enrollment
220 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia